Prevention of contrast-induced renal dysfunction by N-acetylcysteine by Billinger, M et al.
Editorial
Prevention of contrast-induced renal dysfunction by
N-acetylcysteine
Truth or myth?
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There is an increase in the use of radiographic contrast
agents in cardiovascular medicine for diagnostic and
therapeutic interventions. However, these interventions
are becoming more and more popular in elderly and
polymorbide patients, thereby increasing the risk of
contrast-induced complications such as renal dysfunction
and delayed allergic reactions. A particular risk for renal
dysfunction has been attributed to pre-existing renal
dysfunction, diabetic nephropathy, dehydration, drug
interactions and the use of large amounts of contrast,
etc. The reduction in renal function by contrast agents
may cause substantial morbidity and mortality and can
lead to end-stage renal disease.
In an attempt to reduce contrast-associated morbidity
and mortality, several interventions and drugs have been
advocated such as hydration with saline, the use of
isotonic and non-ionic contrast agents as well as admin-
istration of nephroprotective drugs such as theophylline,
dobutamine and atrial natriuretic peptides. The largest
experience exists, however, with the antioxidant
N-acetylcysteine (NAC).
The mechanism of renal dysfunction after exposure to
contrast media is not clear, but seems to be an interplay
of renal haemodynamics, toxic effects on tubular epi-
thelial cells and enhanced oxidative stress. Therefore,
the use of antioxidants such as NAC has been recom-
mended to protect the kidney and to prevent renal
dysfunction.
In this issue of the European Heart Journal Briguori et
al.1 report on the prophylactic administration of NAC in
patients undergoing coronary angiography with a low
dose of a non-ionic, low osmolarity contrast medium.
They tested the hypothesis of a protective effect of high
dose (2×1200 mg) vs standard dose (2×600 mg) NAC given
orally along with saline hydration to prevent contrast-
associated nephrotoxicity. Serum creatinine concen-
trations were similar in the two groups, but there was an
increase in creatinine of at least 0.5 mg/dl after angiog-
raphy in 12 of 109 (11%) patients in the standard dose
group and 4 of 114 (3.5%) in the double dose group,
respectively (P=0.04). Furthermore, the amount of
contrast used (larger or smaller than 140 ml) had a
significant effect on renal dysfunction, i.e. NAC had
no effect on renal function in those with low contrast
dose (<140 ml), whereas in those with high dose
(>140 ml) NAC significantly reduced renal dysfunction
from 18.9% to 5.4% (P=0.04). The authors concluded
that the use of double dose of NAC seems to be
more protective in preventing contrast-induced renal
dysfunction especially in patients with high doses of
contrast medium.
In the second paper of this issue of the European Heart
Journal, Goldenberg et al.2 examined the effect of NAC
in prevention of contrast-induced renal dysfunction. In
this study somewhat higher doses of NAC than standard
dose were given (3×600 mg). Both groups received hydra-
tion with saline (1 ml/kg/h over 24 h). An increase of
more than 0.5 mg/dl in serum creatinine after angiogra-
phy was observed in 10% of the NAC and in 8% of the
control group, respectively (n=ns). The authors con-
cluded that prophylactic administration of oral NAC to
prevent contrast-associated nephrotoxicity in patients
with renal insufficiency undergoing coronary angiography
is not justified.
These two contradictory studies have to be seen in the
light of the complex interplay of pharmacology and
contrast toxicity. Apparently, Briguori et al. make the
point that beside the adjunctive therapy with saline the
amount of contrast (>140) and the dose of the antioxida-
tive NAC play an important role for nephroprotection,
* Corresponding author: Tel.: +41-31-632-3077; Fax: +41-31-382-1069
E-mail address: bernhard.meier@insel.ch (B. Meier).
European Heart Journal (2004) 25, 188–189
0195-668X/04/$ - see front matter © 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
doi:10.1016/j.ehj.2003.10.014
whereas Goldenberg et al. state that the effect of NAC in
patients with mild to moderate renal insufficiency is of
limited value and benefits may be observed only when
appropriate hydration is not possible.
Apart from other studies without saline infusion3,4
most reports5–8 in patients undergoing cardiac catheter-
ization have shown no beneficial effect of NAC as adjunc-
tive therapy to saline infusion. Beneficial effects of NAC
as adjunctive therapy to saline have been reported only
by two other studies namely Briguori and Shyu.1,9
Shyu et al. reported a protective effect of NAC in patients
with high serum creatinine levels (mean 2.8 mg/dl).
Assuming the observation of Briguori and Shyu are correct
following recommendations for preventing renal dysfunc-
tion in patients undergoing cardiac catheterization can
be given:
– Hydration with saline in all patients (1 ml/kg/h 12 h
before and 12 h after the intervention)
– Use of a modern non-ionic, low osmolarity contrast
agent
– Use of high dose NAC (2×1200 mg) in patients with high
creatinine levels (>2.5 mg/d) and large contrast doses
(>140 ml)
In conclusion, patients with renal insufficiency
undergoing diagnostic and therapeutic angiography are
at high risk for developing contrast-induced renal dys-
function. The use of small amounts (<140 ml) of non-
ionic, low osmolarity contrast media with appropriate
hydration 12 h before and 12 h after the intervention
helps to reduce the risk of renal dysfunction. The
addition of the antioxidant NAC (2×1200 mg) may be
useful in patients with high serum creatinine levels
(>2.5 mg/dl) and the use of high doses of contrast
material (>140 ml).
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